Discontinued — last reported Q4 '23
Year-over-year, this metric declined by 100.0%, from $300.00K to $0.00. This decline may warrant attention — for this metric, higher values are generally preferred.
High spending indicates a strong commitment to pipeline growth, though it carries significant execution and regulatory risk.
Acquired In-Process Research and Development (IPR&D) represents the cash paid to acquire research projects that have not...
A hallmark metric for pharmaceutical and biotech firms relying on external innovation.
acquired_ipr_d| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $800.00K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $300.00K | $500.00K | $800.00K | $0.00 | $0.00 |
| QoQ Change | — | — | — | — | — | -100.0% | — | — | — | — | — | +66.7% | +60.0% | -100.0% | — |
| YoY Change | — | — | — | — | — | — | — | — | -100.0% | — | — | — | — | — | -100.0% |